The event will be in the Barradas Auditorium in L’Hospitalet de Llobregat on Friday, February 10, at 7 p.m. The 6th sLHam incorporates a novelty: Together with six woman scientists from IDIBELL, two junior sLHamers from the Bellvitge Institute will participate.
According to the results, brentuximab vedotin is effective and safe for some rare types of cutaneous T-cell lymphomas (LCCT)
The group linked to IDIBELL investigates personalized precision strategies for the interdisciplinary approach to heart failure in its evolutionary phases. Their research will contribute to the objective of the CIBERCV: reduce the impact of cardiovascular diseases and develop actions of excellence in translational cardiovascular research and training.
